Becton, Dickinson and Company NYQ · BDX
Price alert —
Sign in to get a one-time email the moment BDX crosses your price. Free accounts included.
Sign in / create a free accountBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
BDX last traded at $158.17, down 1.1% on the day; that's in the middle part of its 52-week range ($140.11–$187.35). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
The next scheduled earnings report (2026-08-06) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC2 upper, +1.21 ATR from EMA21 — no notable pattern
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC2 upper stretch — standard mean-reversion tier
- · RSI hook from overbought (59)
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 59), the trend is quiet (ADX 15), and volume is about normal (0.8×). On the business side, revenue is growing 5% year over year and the business keeps about 21 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $232.37 (fair range $103–$329); today's price leaves a +33% cushion below that estimate. The model's verdict is “Deep value” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Positive retained earnings
- ✓ Gross margin 47% (pricing power)
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.46 (fragile)
Price implies ~0% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
BDX is a $43.6 billion company, priced at 28× last year's earnings, and it moves more calmly than the market (beta 0.3).
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- 2.90 / 2.77
- Surprise
- +4.5%
- Next report
- 2026-08-06
About
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and …